ME02230B - Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink - Google Patents
Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cinkInfo
- Publication number
- ME02230B ME02230B MEP-2015-149A MEP14915A ME02230B ME 02230 B ME02230 B ME 02230B ME P14915 A MEP14915 A ME P14915A ME 02230 B ME02230 B ME 02230B
- Authority
- ME
- Montenegro
- Prior art keywords
- phosphoinositide
- kinase inhibitors
- binding moiety
- zinc binding
- zinc
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14327109P | 2009-01-08 | 2009-01-08 | |
| US17258009P | 2009-04-24 | 2009-04-24 | |
| EP10729566.9A EP2385832B1 (en) | 2009-01-08 | 2010-01-08 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety |
| PCT/US2010/020495 WO2010080996A1 (en) | 2009-01-08 | 2010-01-08 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02230B true ME02230B (me) | 2016-02-20 |
Family
ID=42316830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-149A ME02230B (me) | 2009-01-08 | 2010-01-08 | Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink |
Country Status (26)
| Country | Link |
|---|---|
| US (10) | US8367663B2 (me) |
| EP (1) | EP2385832B1 (me) |
| JP (3) | JP5452617B2 (me) |
| KR (2) | KR101430424B1 (me) |
| CN (1) | CN102341108B (me) |
| AU (1) | AU2010203512C1 (me) |
| BR (1) | BRPI1004899B8 (me) |
| CA (1) | CA2749228C (me) |
| CY (1) | CY1116797T1 (me) |
| DK (1) | DK2385832T3 (me) |
| EA (1) | EA024252B1 (me) |
| ES (1) | ES2550032T3 (me) |
| HK (1) | HK1164113A1 (me) |
| HR (1) | HRP20150947T1 (me) |
| HU (1) | HUE027615T2 (me) |
| IL (2) | IL213976A (me) |
| ME (1) | ME02230B (me) |
| MX (1) | MX2011007326A (me) |
| PL (1) | PL2385832T3 (me) |
| PT (1) | PT2385832E (me) |
| RS (1) | RS54230B1 (me) |
| SG (2) | SG196815A1 (me) |
| SI (1) | SI2385832T1 (me) |
| SM (1) | SMT201500226B (me) |
| TW (1) | TWI558710B (me) |
| WO (1) | WO2010080996A1 (me) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG196815A1 (en) | 2009-01-08 | 2014-02-13 | Curis Inc | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety |
| TWI499592B (zh) * | 2009-09-09 | 2015-09-11 | Avila Therapeutics Inc | Ｐｉ３激酶抑制劑及其用途 |
| WO2011130628A1 (en) * | 2010-04-16 | 2011-10-20 | Curis, Inc. | Treatment of cancers having k-ras mutations |
| JP5695200B2 (ja) * | 2010-09-10 | 2015-04-01 | ハンジョウ ベンシェン ファーマシューティカル シーオー．， エルティーディー．Ｈａｎｇｚｈｏｕ Ｂｅｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | 複素環アミノベルバミン誘導体、その調製方法及び使用 |
| JP6041808B2 (ja) * | 2010-11-16 | 2016-12-14 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 蛋白質脱アセチル化酵素抑制剤としてのピリミジン水酸基アミド化合物およびその利用方法 |
| ES2617339T3 (es) | 2010-12-16 | 2017-06-16 | Calchan Limited | Derivados de pirrolopirimidina inhibidores de ASK1 |
| US9708299B2 (en) | 2011-01-03 | 2017-07-18 | Genentech, Inc. | Hedgehog antagonists having zinc binding moieties |
| US20140206678A1 (en) * | 2011-01-27 | 2014-07-24 | Kadmon Corporation, Llc | Inhibitors of mtor kinase as anti -viral agent |
| WO2012118978A1 (en) * | 2011-03-03 | 2012-09-07 | The Regents Of The University Of Colorado, A Body Corporate | Methods for treating oncovirus positive cancers |
| AU2012236367B2 (en) * | 2011-04-01 | 2014-10-09 | Curis, Inc. | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| US20130102595A1 (en) * | 2011-04-15 | 2013-04-25 | Curis, Inc. | Treatment of cancers having k-ras mutations |
| EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
| EP3048106B1 (en) * | 2011-11-23 | 2019-11-06 | Cancer Research Technology Limited | Thienopyrimidine as inhibitors of atypical protein kinase c |
| AU2014282769A1 (en) | 2013-06-21 | 2015-12-17 | Lupin Limited | Substituted heterocyclic compounds as CRAC modulators |
| WO2014207648A1 (en) | 2013-06-24 | 2014-12-31 | Lupin Limited | Chromane and chromene derivatives and their use as crac modulators |
| KR20160099081A (ko) | 2013-07-26 | 2016-08-19 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조합 방법 |
| JP6626437B2 (ja) | 2013-10-08 | 2019-12-25 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | ヒストンデアセチラーゼ阻害剤とＨｅｒ２阻害剤またはＰＩ３Ｋ阻害剤のいずれかの組み合わせ |
| ES2862126T3 (es) | 2013-10-10 | 2021-10-07 | Acetylon Pharmaceuticals Inc | Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa |
| EP4137135A1 (en) | 2013-10-24 | 2023-02-22 | Mayo Foundation for Medical Education and Research | Treatment of polycystic diseases with an hdac6 inhibitor |
| ES2806258T3 (es) | 2013-12-03 | 2021-02-17 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores |
| CN104725301A (zh) * | 2013-12-20 | 2015-06-24 | 北京蓝贝望生物医药科技股份有限公司 | 一种1,2-二氢吡啶-2-酮衍生物的制备方法 |
| US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
| EP3166603B1 (en) | 2014-07-07 | 2020-02-12 | Acetylon Pharmaceuticals, Inc. | Treatment of leukemia with histone deacetylase inhibitors |
| MY194204A (en) | 2014-08-04 | 2022-11-21 | Nuevolution As | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
| CN104292242B (zh) * | 2014-09-18 | 2017-05-17 | 广州必贝特医药技术有限公司 | 噻吩嘧啶类化合物和制剂及其制备方法和应用 |
| US9937174B2 (en) | 2014-12-05 | 2018-04-10 | University of Modena and Reggio Emilia | Combinations of histone deacetylase inhibitors and bendamustine |
| WO2016092556A1 (en) * | 2014-12-11 | 2016-06-16 | Natco Pharma Limited | 7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs |
| AU2016250972B2 (en) * | 2015-04-21 | 2019-01-17 | Chengdu Zenitar Biomedical Technology Co., Ltd. | Purinyl-n-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof |
| US10272084B2 (en) | 2015-06-01 | 2019-04-30 | Regenacy Pharmaceuticals, Llc | Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy |
| CN105037345B (zh) * | 2015-06-09 | 2019-01-25 | 天津渤海职业技术学院 | 抗肿瘤化合物、其制备方法和用途 |
| WO2017090058A1 (en) * | 2015-11-23 | 2017-06-01 | Council Of Scientific & Industrial Research | Fused pyrimidines as isoform selective phosphoinositide-3-kinase-alpha inhibitors and process for preparation thereof |
| US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
| JP2019515909A (ja) | 2016-04-19 | 2019-06-13 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 慢性リンパ性白血病の治療を目的とするｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との配合物 |
| AU2017315343A1 (en) | 2016-08-24 | 2019-02-28 | Arqule, Inc. | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
| MA46728A (fr) * | 2016-11-02 | 2019-09-11 | Curis Inc | Polythérapie avec un inhibiteur de phosphoinositide 3-kinase avec une fraction de liaison au zinc |
| MX2019005822A (es) * | 2016-11-18 | 2019-09-09 | Cystic Fibrosis Found Therapeutics Inc | Pirrolopirimidinas como potenciadores de cftr. |
| US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
| CA3052466A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| CN108623491B (zh) * | 2017-03-24 | 2020-12-22 | 联化科技股份有限公司 | 一种卤代苯甲酰胺化合物的制备方法 |
| CN107163061A (zh) * | 2017-04-14 | 2017-09-15 | 江西科技师范大学 | 含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用 |
| SG11202102343QA (en) | 2018-09-11 | 2021-04-29 | Curis Inc | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| KR20210124310A (ko) | 2019-02-06 | 2021-10-14 | 벤테라, 인코포레이티드 | 국소 포스포이노시티드 3-키나제 억제제 |
| MX2022007265A (es) | 2019-12-20 | 2022-09-09 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
| MX2022012260A (es) | 2020-03-31 | 2022-11-30 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
| EP4126875A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
| WO2022152229A1 (zh) * | 2021-01-15 | 2022-07-21 | 深圳微芯生物科技股份有限公司 | 一类吗啉衍生物及其制备方法和应用 |
| CN117203212A (zh) * | 2021-03-29 | 2023-12-08 | 株式会社钟化 | (2-甲基嘧啶-5-基)硼酸衍生物的制造方法 |
| CN113754680B (zh) * | 2021-09-28 | 2022-07-22 | 云白药征武科技(上海)有限公司 | 一种α氟代酰基哌嗪衍生物及其制备和应用 |
| CN118019744A (zh) * | 2021-09-30 | 2024-05-10 | 韩美药品株式会社 | PIKfyve激酶抑制剂 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5502187A (en) * | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| AU6410699A (en) * | 1998-10-13 | 2000-05-01 | Chris Cheah | Method and system for controlled distribution of information over a network |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| CA2407593C (en) * | 2000-04-27 | 2011-01-11 | Yamanouchi Pharmaceutical Co. Ltd. | Fused heteroaryl derivatives |
| DE60321548D1 (de) | 2002-03-13 | 2008-07-24 | Janssen Pharmaceutica Nv | Carbonylamino- derivativate als neue inhibitoren von histone deacetylase |
| AU2003218738B2 (en) | 2002-03-13 | 2009-01-08 | Janssen Pharmaceutica N.V. | Sulfonyl-derivatives as novel inhibitors of histone deacetylase |
| EP1485099B1 (en) | 2002-03-13 | 2010-07-07 | Janssen Pharmaceutica N.V. | Inhibitors of histone deacetylase |
| KR20040094672A (ko) | 2002-03-13 | 2004-11-10 | 얀센 파마슈티카 엔.브이. | 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체 |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| WO2004067535A1 (ja) * | 2003-01-29 | 2004-08-12 | Takeda Pharmaceutical Company Limited | チエノピリミジン化合物およびその用途 |
| EP1750727A2 (en) * | 2004-04-23 | 2007-02-14 | Exelixis, Inc. | Kinase modulators and methods of use |
| US7218492B2 (en) * | 2004-09-17 | 2007-05-15 | Electronic Polymers, Inc. | Devices and systems for electrostatic discharge suppression |
| JP4862654B2 (ja) | 2004-10-08 | 2012-01-25 | アステラス製薬株式会社 | 芳香環縮合ピリミジン誘導体 |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| EP1855760A2 (en) | 2005-02-03 | 2007-11-21 | TopoTarget UK Limited | Combination therapies using hdac inhibitors |
| WO2006122926A1 (en) | 2005-05-18 | 2006-11-23 | Janssen Pharmaceutica N.V. | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase |
| US7731753B2 (en) * | 2005-09-01 | 2010-06-08 | Spinal Kinetics, Inc. | Prosthetic intervertebral discs |
| AU2006306462B2 (en) * | 2005-10-24 | 2012-07-26 | Biomet 3I, Llc | Methods for manufacturing dental implant components |
| JP2007151829A (ja) * | 2005-12-05 | 2007-06-21 | Bridgestone Sports Co Ltd | ゴルフクラブヘッド |
| US8114876B2 (en) | 2006-01-19 | 2012-02-14 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| US7834011B2 (en) | 2006-01-19 | 2010-11-16 | Janssen Pharmaceutica N.V. | Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase |
| WO2007082880A1 (en) | 2006-01-19 | 2007-07-26 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| TWI409268B (zh) | 2006-04-26 | 2013-09-21 | Hoffmann La Roche | 醫藥化合物 |
| EP2402347A1 (en) | 2006-04-26 | 2012-01-04 | F. Hoffmann-La Roche AG | Pharmaceutical compounds |
| US8252792B2 (en) | 2006-04-26 | 2012-08-28 | F. Hoffman-La Roche Ag | Pyrimidine derivatives as PI3K inhibitors |
| MX2008013583A (es) * | 2006-04-26 | 2008-10-31 | Genentech Inc | Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen. |
| EP2018366A4 (en) | 2006-05-16 | 2010-08-04 | Univ Mcgill | HYBRID MOLECULES HAVING MIXED PROPERTIES OF VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITOR |
| US20080161320A1 (en) | 2006-09-11 | 2008-07-03 | Xiong Cai | Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety |
| AU2007296740B2 (en) | 2006-09-11 | 2012-09-27 | Curis, Inc. | Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| JP5580592B2 (ja) * | 2006-09-11 | 2014-08-27 | キュリス，インコーポレイテッド | 亜鉛結合部分を含むキナゾリン系ｅｇｆｒインヒビター |
| WO2008033744A2 (en) * | 2006-09-11 | 2008-03-20 | Curis, Inc. | Dna methyl transferase inhibitors containing a zinc binding moiety |
| KR101433629B1 (ko) | 2006-09-11 | 2014-08-27 | 쿠리스 인코퍼레이션 | 아연 결합 부분을 함유한 티로신 키나아제 억제제 |
| CA2662587C (en) * | 2006-09-11 | 2013-08-06 | Curis, Inc. | Quinazoline based egfr inhibitors |
| WO2008033747A2 (en) * | 2006-09-11 | 2008-03-20 | Curis, Inc. | Multi-functional small molecules as anti-proliferative agents |
| US8399452B2 (en) | 2006-10-28 | 2013-03-19 | Methylgene Inc. | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors |
| US9487533B2 (en) | 2006-12-07 | 2016-11-08 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| EP2114949A1 (en) * | 2006-12-07 | 2009-11-11 | F.Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| PE20090519A1 (es) | 2007-02-15 | 2009-05-29 | Novartis Ag | Composicion farmaceutica que contiene n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)-etil]-amino]-metil]-fenil]-2e-2-propenamida |
| JP2010522163A (ja) | 2007-03-20 | 2010-07-01 | キュリス，インコーポレイテッド | 亜鉛結合部位を含むＲａｆキナーゼインヒビター |
| WO2009036057A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Antiproliferative agents containing a zinc binding moiety |
| WO2009036020A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Mek inhibitors containing a zinc binding moiety |
| TW200922590A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | VEGFR inhibitors containing a zinc binding moiety |
| TW200922564A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| PE20090678A1 (es) | 2007-09-12 | 2009-06-27 | Genentech Inc | Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso |
| WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
| CN101883774A (zh) * | 2007-10-16 | 2010-11-10 | 惠氏有限责任公司 | 噻吩并嘧啶和吡唑并嘧啶化合物及其用作mtor激酶和pi3激酶抑制剂的用途 |
| JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| WO2009058895A1 (en) | 2007-10-30 | 2009-05-07 | Syndax Pharmaceuticals, Inc. | Administration of an inhibitor of hdac and an mtor inhibitor |
| WO2009086012A1 (en) | 2007-12-20 | 2009-07-09 | Curis, Inc. | Aurora inhibitors containing a zinc binding moiety |
| JP2011525535A (ja) | 2008-06-24 | 2011-09-22 | 武田薬品工業株式会社 | ＰＩ３Ｋ／ｍＴＯＲ阻害剤 |
| WO2009155659A1 (en) | 2008-06-27 | 2009-12-30 | The University Of Queensland | Combination therapy |
| SG196815A1 (en) * | 2009-01-08 | 2014-02-13 | Curis Inc | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety |
| WO2010105008A2 (en) | 2009-03-12 | 2010-09-16 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
| AU2010314287A1 (en) | 2009-10-12 | 2012-05-03 | F. Hoffmann-La Roche Ag | Combinations of a PI3K inhibitor and a MEK inhibitor |
| WO2011130628A1 (en) * | 2010-04-16 | 2011-10-20 | Curis, Inc. | Treatment of cancers having k-ras mutations |
| AU2012236367B2 (en) * | 2011-04-01 | 2014-10-09 | Curis, Inc. | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| US20130102595A1 (en) | 2011-04-15 | 2013-04-25 | Curis, Inc. | Treatment of cancers having k-ras mutations |
-
2010
- 2010-01-08 SG SG2014002737A patent/SG196815A1/en unknown
- 2010-01-08 EP EP10729566.9A patent/EP2385832B1/en active Active
- 2010-01-08 PT PT107295669T patent/PT2385832E/pt unknown
- 2010-01-08 AU AU2010203512A patent/AU2010203512C1/en active Active
- 2010-01-08 SG SG2011049848A patent/SG172908A1/en unknown
- 2010-01-08 TW TW099100348A patent/TWI558710B/zh active
- 2010-01-08 WO PCT/US2010/020495 patent/WO2010080996A1/en active Application Filing
- 2010-01-08 EA EA201101053A patent/EA024252B1/ru unknown
- 2010-01-08 ME MEP-2015-149A patent/ME02230B/me unknown
- 2010-01-08 PL PL10729566T patent/PL2385832T3/pl unknown
- 2010-01-08 BR BRPI1004899A patent/BRPI1004899B8/pt active IP Right Grant
- 2010-01-08 HU HUE10729566A patent/HUE027615T2/en unknown
- 2010-01-08 CN CN201080010977.1A patent/CN102341108B/zh active Active
- 2010-01-08 RS RS20150596A patent/RS54230B1/en unknown
- 2010-01-08 JP JP2011545452A patent/JP5452617B2/ja active Active
- 2010-01-08 ES ES10729566.9T patent/ES2550032T3/es active Active
- 2010-01-08 SI SI201031013T patent/SI2385832T1/sl unknown
- 2010-01-08 KR KR1020117018181A patent/KR101430424B1/ko active IP Right Grant
- 2010-01-08 DK DK10729566.9T patent/DK2385832T3/en active
- 2010-01-08 US US12/684,594 patent/US8367663B2/en active Active
- 2010-01-08 CA CA2749228A patent/CA2749228C/en active Active
- 2010-01-08 KR KR1020147014945A patent/KR20140094590A/ko not_active Application Discontinuation
- 2010-01-08 MX MX2011007326A patent/MX2011007326A/es active IP Right Grant
-
2011
- 2011-04-01 US US13/078,769 patent/US8461157B2/en active Active
- 2011-07-07 IL IL213976A patent/IL213976A/en active IP Right Grant
-
2012
- 2012-05-04 HK HK12104359.3A patent/HK1164113A1/xx unknown
-
2013
- 2013-05-13 US US13/892,373 patent/US8906909B2/en active Active
- 2013-12-27 JP JP2013271719A patent/JP5762520B2/ja active Active
-
2014
- 2014-11-12 US US14/539,327 patent/US9725461B2/en active Active
-
2015
- 2015-03-12 IL IL237727A patent/IL237727A0/en unknown
- 2015-06-09 JP JP2015116323A patent/JP2015187145A/ja not_active Withdrawn
- 2015-09-08 HR HRP20150947TT patent/HRP20150947T1/hr unknown
- 2015-09-24 SM SM201500226T patent/SMT201500226B/xx unknown
- 2015-10-13 CY CY20151100919T patent/CY1116797T1/el unknown
-
2017
- 2017-06-29 US US15/637,448 patent/US10336770B2/en active Active
-
2019
- 2019-05-29 US US16/425,316 patent/US10676482B2/en active Active
-
2020
- 2020-05-12 US US15/930,103 patent/US10894795B2/en active Active
- 2020-12-23 US US17/132,399 patent/US11261195B2/en active Active
-
2022
- 2022-01-27 US US17/585,701 patent/US11597732B2/en active Active
-
2023
- 2023-01-13 US US18/097,038 patent/US20230227467A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL237727A0 (en) | Inhibitors of phosphoinositide 3-kinase with a zinc-binding group | |
| IL248597B (en) | A phosphoinositide-3-kinase inhibitor with a zinc binding site | |
| GB2473135B (en) | A cowl-top cover | |
| IL215259A0 (en) | Autotaxin inhibitors | |
| GB2475221B (en) | A book | |
| HK1170566A1 (en) | Secernin-1 as a marker for cancer -1 | |
| EP2507309A4 (en) | NETWORKING RESOURCES | |
| HK1175487A1 (en) | Composition for a structural adhesive | |
| IL214028A0 (en) | A novel cyanopyrimidine derivative | |
| GB201020402D0 (en) | Cover for a chimmey | |
| GB0811632D0 (en) | A cover | |
| GB2500516B (en) | A book | |
| MY157991A (en) | A floating trash rack | |
| GB0901731D0 (en) | A polymer for metal sequetration | |
| HK1144138A2 (en) | A convenient closetool | |
| AU326741S (en) | A cartridge | |
| GB0907840D0 (en) | Automatic bookmark |